Overcoming cancer therapeutic bottleneck by drug repurposing

Abstract

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The “treasure trove” of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono- or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake.

Cited by papers we hold 8

• Drug repurposing for cancer therapy · 2024
  No notice
• Multifunctional nanoparticle-mediated combining therapy for human diseases · 2024
  No notice
• Unveiling the mechanisms and challenges of cancer drug resistance · 2024
  No notice
• Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy · 2023
  No notice
• lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation · 2022
  Not checked
• Recent advances and limitations of mTOR inhibitors in the treatment of cancer · 2022
  No notice
• Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management · 2022
  No notice
• Phytochemicals as a Complement to Cancer Chemotherapy: Pharmacological Modulation of the Autophagy-Apoptosis Pathway · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.